Abstract
Alzheimer’s disease (AD) affects several important molecules in brain metabolism. The resulting neurochemical changes can be quantified non-invasively in localized brain regions using in vivo single-voxel proton magnetic resonance spectroscopy (SV 1H MRS). Although the often heralded diagnostic potential of MRS in AD largely remains unfulfilled, more recent use of high magnetic fields has led to significantly improved signal-to-noise ratios and spectral resolutions, thereby allowing clinical applications with increased measurement reliability. The present article provides a comprehensive review of SV 1H MRS studies on AD at high magnetic fields (3.0 Tesla and above). This review suggests that patterned regional differences and longitudinal alterations in several neurometabolites are associated with clinically established AD. Changes in multiple metabolites are identifiable even at early stages of AD development. By combining information of neurochemicals in different brain regions revealing either pathological or compensatory changes, high field MRS can be evaluated in AD diagnosis and in the detection of treatment effects. To achieve this, standardization of data acquisition and analytical approaches is needed.
Keywords: Alzheimer's disease, brain, high-field, metabolite, mild cognitive impairment, neurochemical, proton magnetic resonance spectroscopy.
Current Alzheimer Research
Title:Advances in High-Field Magnetic Resonance Spectroscopy in Alzheimer’s Disease
Volume: 11 Issue: 4
Author(s): Ningnannan Zhang, Xiaowei Song, Robert Bartha, Steven Beyea, Ryan D’Arcy, Yunting Zhang and Kenneth Rockwood
Affiliation:
Keywords: Alzheimer's disease, brain, high-field, metabolite, mild cognitive impairment, neurochemical, proton magnetic resonance spectroscopy.
Abstract: Alzheimer’s disease (AD) affects several important molecules in brain metabolism. The resulting neurochemical changes can be quantified non-invasively in localized brain regions using in vivo single-voxel proton magnetic resonance spectroscopy (SV 1H MRS). Although the often heralded diagnostic potential of MRS in AD largely remains unfulfilled, more recent use of high magnetic fields has led to significantly improved signal-to-noise ratios and spectral resolutions, thereby allowing clinical applications with increased measurement reliability. The present article provides a comprehensive review of SV 1H MRS studies on AD at high magnetic fields (3.0 Tesla and above). This review suggests that patterned regional differences and longitudinal alterations in several neurometabolites are associated with clinically established AD. Changes in multiple metabolites are identifiable even at early stages of AD development. By combining information of neurochemicals in different brain regions revealing either pathological or compensatory changes, high field MRS can be evaluated in AD diagnosis and in the detection of treatment effects. To achieve this, standardization of data acquisition and analytical approaches is needed.
Export Options
About this article
Cite this article as:
Zhang Ningnannan, Song Xiaowei, Bartha Robert, Beyea Steven, D’Arcy Ryan, Zhang Yunting and Rockwood Kenneth, Advances in High-Field Magnetic Resonance Spectroscopy in Alzheimer’s Disease, Current Alzheimer Research 2014; 11 (4) . https://dx.doi.org/10.2174/1567205011666140302200312
DOI https://dx.doi.org/10.2174/1567205011666140302200312 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia
Current Alzheimer Research Brain Aging in African-Americans: The Atherosclerosis Risk in Communities (ARIC) Experience
Current Alzheimer Research Thin, Stubby or Mushroom: Spine Pathology in Alzheimers Disease
Current Alzheimer Research Tailored Multi-Target Agents. Applications and Design Considerations
Current Pharmaceutical Design BACE1: Expression, Regulation, and Therapeutic Potential of the Major Alzheimer’s Disease Beta-Secretase
Current Enzyme Inhibition Glucolipotoxicity-induced Oxidative Stress is Related to Mitochondrial Dysfunction and Apoptosis of Pancreatic β-cell
Current Diabetes Reviews CRISPR/Cas9 in Stem Cell Research: Current Application and Future Perspective
Current Stem Cell Research & Therapy The Glial Sodium-Calcium Exchanger: A New Target for Nitric Oxide- Mediated Cellular Toxicity
Current Protein & Peptide Science Racial Differences in Gray Matter Integrity by Diffusion Tensor in Black and White Octogenarians
Current Alzheimer Research A Protective Role of Translocator Protein in Alzheimer’s Disease Brain
Current Alzheimer Research Induced Adaptive Resistance to Nitrooxidative Stress in the CNS: Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry Platelets and Platelet Interaction with Progenitor Cells in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology Glycyrrhizic Acid Ameliorates Cognitive Impairment in a Rat Model of Vascular Dementia Associated with Oxidative Damage and Inhibition of Voltage-Gated Sodium Channels
CNS & Neurological Disorders - Drug Targets Multiple Species Metabolism of PHA-568487, A Selective α7 Nicotinic Acetylcholine Receptor Agonist
Drug Metabolism Letters Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Disease
Current Pharmaceutical Design New Approaches in Nuclear Medicine for Early Diagnosis of Alzheimers Disease
Current Alzheimer Research Behavioral Experimental Paradigms for the Evaluation of Drug’s Influence on Cognitive Functions: Interpretation of Associative, Spatial/Nonspatial and Working Memory
CNS & Neurological Disorders - Drug Targets Targeting the PAC1 Receptor for Neurological and Metabolic Disorders
Current Topics in Medicinal Chemistry Stability in Cognitive Function Over 18 Years: Prevalence and Predictors among Older Mexican Americans
Current Alzheimer Research Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease
Current Alzheimer Research